TRACON Pharmaceuticals, Inc. (TCON) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
4350 LA JOLLA VILLAGE DRIVE SAN DIEGO, CA 92122 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 17,500 | 17,200 | 13,600 | 16,600 | 24,100 | 29,900 | 25,600 | ||
| Cash and cash equivalents | 17,433 | 17,037 | 13,580 | 16,640 | 24,072 | 29,901 | 25,580 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | 67 | 163 | 20 | (40) | 28 | (1) | 20 | ||
| Other undisclosed current assets | 728 | 820 | 556 | 693 | 836 | 1,242 | 589 | ||
| Total current assets: | 18,228 | 18,020 | 14,156 | 17,293 | 24,936 | 31,142 | 26,189 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,123 | ||||||||
| Property, plant and equipment | 51 | 51 | 50 | 49 | 50 | 49 | 40 | ||
| Restricted cash and investments | 67 | 175 | |||||||
| Other undisclosed noncurrent assets | 1,420 | 1,471 | 1,522 | 1,571 | 1,617 | 574 | |||
| Total noncurrent assets: | 1,241 | 1,646 | 1,521 | 1,571 | 1,621 | 1,666 | 614 | ||
| TOTAL ASSETS: | 19,469 | 19,666 | 15,677 | 18,864 | 26,557 | 32,808 | 26,803 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,457 | 2,566 | 2,122 | 816 | 1,532 | 1,128 | 945 | ||
| Employee-related liabilities | ✕ | 1,283 | 1,061 | 816 | 1,532 | 1,128 | 945 | ||
| Accrued liabilities | 1,457 | 1,283 | 1,061 | ||||||
| Debt | 11,107 | 698 | 10,753 | 2,079 | 2,761 | ||||
| Other undisclosed current liabilities | 9,807 | 9,194 | 9,941 | 13,439 | 1,391 | 9,527 | 11,182 | ||
| Total current liabilities: | 22,371 | 11,760 | 12,063 | 14,953 | 13,676 | 12,734 | 14,888 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 9,095 | ||||||||
| Long-term debt, excluding current maturities | 9,095 | ||||||||
| Liabilities, other than long-term debt | 969 | 1,446 | 1,072 | 1,121 | 1,167 | 1,211 | |||
| Other liabilities | 969 | 1,446 | 1,072 | 1,121 | 1,167 | 1,211 | |||
| Total noncurrent liabilities: | 969 | 10,541 | 1,072 | 1,121 | 1,167 | 1,211 | |||
| Total liabilities: | 23,340 | 22,301 | 13,135 | 16,074 | 14,843 | 13,945 | 14,888 | ||
| Equity | |||||||||
| Equity, attributable to parent | (7,151) | (2,635) | 2,542 | 2,790 | 11,714 | 18,863 | 11,915 | ||
| Common stock | 23 | 22 | 21 | 20 | 19 | 19 | 16 | ||
| Additional paid in capital | 229,737 | 227,257 | 226,000 | 220,019 | 219,471 | 218,908 | 205,011 | ||
| Accumulated deficit | (236,911) | (229,914) | (223,479) | (217,249) | (207,776) | (200,064) | (193,112) | ||
| Total equity: | (7,151) | (2,635) | 2,542 | 2,790 | 11,714 | 18,863 | 11,915 | ||
| Other undisclosed liabilities and equity | 3,280 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 19,469 | 19,666 | 15,677 | 18,864 | 26,557 | 32,808 | 26,803 | ||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 346 | |||||||
| Gross profit: | 346 | |||||||
| Operating expenses | (5,832) | (6,377) | (6,239) | (9,446) | (7,663) | (6,881) | (9,194) | |
| Operating loss: | (5,832) | (6,377) | (6,239) | (9,446) | (7,663) | (6,881) | (8,848) | |
| Nonoperating income (expense) | (1,165) | (58) | 9 | (27) | (49) | (71) | (91) | |
| Loss from continuing operations: | (6,997) | (6,435) | (6,230) | (9,473) | (7,712) | (6,952) | (8,939) | |
| Loss before gain (loss) on sale of properties: | ✕ | (6,435) | (6,230) | (9,473) | (7,712) | (6,952) | (8,939) | |
| Net loss available to common stockholders, diluted: | (6,997) | (6,435) | (6,230) | (9,473) | (7,712) | (6,952) | (8,939) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (6,997) | (6,435) | (6,230) | (9,473) | (7,712) | (6,952) | (8,939) | |
| Comprehensive loss, net of tax, attributable to parent: | (6,997) | (6,435) | (6,230) | (9,473) | (7,712) | (6,952) | (8,939) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.